✦ LIBER ✦

Sequence Therapy in Patients with Metastatic Renal Cell Carcinoma: Comparison of Common Targeted Treatment Options Following Failure of Receptor Tyrosine Kinase Inhibitors

✍ Scribed by Jonas Busch; Christoph Seidel; Carsten Kempkensteffen; Manfred Johannsen; Ingmar Wolff; Stefan Hinz; Ahmed Magheli; Kurt Miller; Viktor Grünwald; Steffen Weikert

Book ID: 113612436
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 518 KB
Volume: 60
Category: Article
ISSN: 0302-2838
DOI: 10.1016/j.eururo.2011.07.037

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sequential mTOR inhibitor treatment with

Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors

✍ Steffen Weikert, Carsten Kempkensteffen, Jonas Busch… 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 243 KB

Sequential use of mammalian target of ra

Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors

✍ Kumano, Masafumi; Miyake, Hideaki; Harada, Ken-ichi; Fujisawa, Masato 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 297 KB

MP57-03 SEQUENTIAL USE OF MAMMALIAN TARG

MP57-03 SEQUENTIAL USE OF MAMMALIAN TARGET OF RAPAMYCIN INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA FOLLOWING FAILURE OF TYROSINE KINASE INHIBITORS

✍ Harada, Ken-ichi; Miyake, Hideaki; Fujisawa, Masato 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 143 KB

725 SEQUENTIAL USE OF MTOR -INHIBITORS I

725 SEQUENTIAL USE OF MTOR -INHIBITORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT

✍ J. Busch; C. Kempkensteffen; V. Grünwald; L. Weinkauf; S. Hinz; A. Magheli; K. M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 176 KB

95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM)

95 SEQUENTIAL USE OF TEMSIROLIMUS (TEM) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): SAFETY AND EFFICACY FOLLOWING FAILURE OF RECEPTOR TYROSINE KINASE INHIBITOR (TKI) TREATMENT

✍ S. Weikert; C. Kempkensteffen; K. Zimmermann; V. Grünwald; A. Floercken; J. West 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 81 KB

1143 Treatment of patients with metastat

1143 Treatment of patients with metastatic papillary-type II and clear-cell renal cell carcinoma – comparison of the survival with tyrosine kinase inhibitors

✍ Casuscelli, J.; Szabados, B.; Buchner, A.; Stief, C.G.; Staehler, M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 199 KB